The therapeutic potential of PD156707 and related butenolide endothelin antagonists

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.1, 1999-01, pp. : 71-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Potential for Endothelin Receptor Antagonists in Cardiovascular Disorders

By Spieker L.E. Noll G. Lüscher T.F.

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 4, 2001-04 ,pp. : 293-303

Adis International

Access to resources Recommend Favorite

Development of endothelin receptor antagonists as potential therapeutic agents

By Ergul Adviye

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 1, 2003-01 ,pp. : 33-44

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of endothelin receptor antagonists in diabetes

By Chakrabarti S. Cukiernik M. Mukherjee S. Chen S.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2873-2888

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension

By Tilton Ronald G Brock Tommy A Dixon Richard AF

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 7, 2001-07 ,pp. : 1291-1308

Informa Healthcare

Access to resources Recommend Favorite

Effects of endothelin ET A receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits

By Ignasiak D.P. McClanahan T.B. Saganek L.J. Potoczak R.E. Hallak H. Gallagher K.P.

European Journal of Pharmacology, Vol. 321, Iss. 3, 1997-03 ,pp. : 295-300

Elsevier

Access to resources Recommend Favorite